X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals (Nasdaq:XFOR) granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan, effective May 29, 2026.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq:XFOR) granted inducement stock options to new employees under its 2019 Inducement Equity Incentive Plan, effective May 29, 2026. The awards cover 160,000 shares at an exercise price of $4.31 per share, with a ten-year term and four-year vesting schedule.

Positive

• Inducement options covering 160,000 shares granted to attract new employees
• Exercise price of $4.31 set at market closing price on May 29, 2026
• Four-year vesting structure supports employee retention over the long term

Negative

• Potential future dilution from up to 160,000 new shares if options are exercised

Argus Jun 2 session

-1.70% close to close Open Argus

Details

News Market Reaction – XFOR

In the Jun 2 session, XFOR declined 1.70%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement option grants for new hires: 160,000 options under the ...

Analysis

This announcement details routine inducement option grants for new hires: 160,000 options under the 2019 Inducement Plan, priced at $4.31 with a four-year vesting schedule and a 10-year term. It follows recent equity plan approvals and an effective $300,000,000 shelf registration that includes up to $75,000,000 in ATM capacity. Investors tracking X4’s story often focus on regulatory milestones for XOLREMDI, progress in the Phase 3 4WARD trial, cash runway, and any subsequent use of the shelf.

Key Figures

Inducement options: 160,000 shares Option term: 10 years Exercise price: $4.31 per share +4 more

Inducement options

160,000 shares

Aggregate options granted under 2019 Inducement Plan

Option term

10 years

Contractual life of inducement stock options

Exercise price

$4.31 per share

Equal to XFOR closing price on May 29, 2026

Initial vesting

25%

Portion of each option vesting after 12 months

Initial cliff

12 months

Time until first 25% of options vest

Remainder vesting

36 months

Remaining shares vest monthly over following 3 years

Vesting period

4 years

Total vesting duration for inducement options

Historical Context

5 past events · Latest: May 27

5 events

1. May 27

   Conference presentation

   24h Move

   +0.8%

   Jefferies conference appearance with webcast access for investors.

2. May 06

   Earnings and update

   24h Move

   +4.3%

   Q1 2026 results with EU approval, trial progress, and cash runway to 2028.

3. Apr 29

   EU approval

   24h Move

   -0.5%

   European Commission marketing authorization for XOLREMDI in WHIM syndrome.

4. Apr 01

   Inducement grants

   24h Move

   -2.5%

   Inducement stock options under 2019 plan with standard vesting and pricing.

5. Mar 17

   Earnings and update

   24h Move

   +18.8%

   FY 2025 results, strong cash position, 4WARD enrollment on track, positive CHMP.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on May 29, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 160,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $4.31 per share, which is equal to the closing price of X4’s common stock on May 29, 2026. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals

X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI® for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
ir@x4pharma.com

Source: X4 Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did X4 Pharmaceuticals (XFOR) announce on June 1, 2026?

X4 Pharmaceuticals announced stock option inducement grants covering 160,000 shares to new employees. According to X4, these options were issued under the 2019 Inducement Equity Incentive Plan and are intended as a material inducement for individuals who were not previously company employees.

What are the key terms of the new X4 Pharmaceuticals (XFOR) inducement stock options?

The inducement options have a ten-year term and a $4.31 exercise price. According to X4, $4.31 equals the closing price on May 29, 2026, and each award is subject to the 2019 Inducement Plan and an applicable award agreement.

How do the X4 Pharmaceuticals (XFOR) inducement options vest for new employees?

The inducement options vest over four years with a 25% cliff after 12 months. According to X4, the remaining 75% of shares vest monthly over the following 36 months, contingent on each employee’s continued employment through the applicable vesting dates.

Why were X4 Pharmaceuticals (XFOR) inducement awards granted under Nasdaq Rule 5635(c)(4)?

The awards were granted as a material inducement for new hires under Nasdaq Rule 5635(c)(4). According to X4, the Compensation Committee approved these options specifically for individuals who were not previously employees, using the 2019 Inducement Equity Incentive Plan.

How could the new X4 Pharmaceuticals (XFOR) inducement options affect the company’s share count?

If fully exercised, the options would result in issuing up to 160,000 shares. According to X4, these options are rights to purchase common stock, so any exercises would increase the number of outstanding shares by the exercised amount.